Bacterial cellulose (BC) is a versatile biopolymer with better material properties, such as
purity, high degree of porosity, relative high permeability to liquid and gases, high water …

The purpose of making a “biobetter” biologic is to improve on the salient characteristics of a
known biologic for which there is, minimally, clinical proof of concept or, maximally …

Importantly, with the advent of hybridoma and recombinant DNA technologies, the limitations
associated with the extraction and purification of pharmaceutical proteins from animal …

With a growing number of protein therapeutics being developed, many of them exhibiting a
short plasma half-life, half-life extension strategies find increasing attention by the biotech …

Research on mesoporous materials for biomedical purposes has experienced an
outstanding increase during recent years. Since 2001, when MCM‐41 was first proposed as …

The safety and efficacy of protein therapeutics are limited by three interrelated
pharmaceutical issues, in vitro and in vivo instability, immunogenicity and shorter half-lives …

Over the past 5 years, a new generation of highly potent and broadly neutralizing HIV-1
antibodies has been identified. These antibodies can protect against lentiviral infection in …

In recent decades, protein-based therapeutics have substantially expanded the field of
molecular pharmacology due to their outstanding potential for the treatment of disease …

During their development and administration, protein-based drugs routinely display
suboptimal therapeutic efficacies due to their poor physicochemical and pharmacological …

The principles of inter‐species dose extrapolation are poorly understood and applied. We
provide an overview of the principles underlying dose scaling for size and dose adjustment …